Mirum Pharmaceuticals (MIRM) Revenue (2021 - 2026)

Mirum Pharmaceuticals' Revenue history runs 6 years deep, the most recent figure standing at $159.9 million for Q1 2026.

• In Q1 2026, Revenue rose 43.28% year-over-year to $159.9 million; the TTM figure through Mar 2026 stood at $569.6 million (up 50.19% YoY), while the FY2025 annual figure was $521.3 million, up 54.74% from the prior year.
• Revenue was $159.9 million for Q1 2026 at Mirum Pharmaceuticals, up from $148.9 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $159.9 million in Q1 2026 to a low of $12.9 million in Q1 2022.
• Historically, Revenue has averaged $75.4 million across 5 years, with a median of $69.6 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Revenue jumped 789.29% in 2022, then surged 42.93% in 2024.
• A 5-year view of Revenue shows it stood at $27.9 million in 2022, then soared by 149.24% to $69.6 million in 2023, then soared by 42.93% to $99.4 million in 2024, then surged by 49.81% to $148.9 million in 2025, then climbed by 7.35% to $159.9 million in 2026.
• The last three Revenue figures came in at $159.9 million (Q1 2026), $148.9 million (Q4 2025), and $133.0 million (Q3 2025), per Business Quant data.